2023
Clinical Phenotyping with an Outcomes-driven Mixture of Experts for Patient Matching and Risk Estimation
Hurley N, Dhruva S, Desai N, Ross J, Ngufor C, Masoudi F, Krumholz H, Mortazavi B. Clinical Phenotyping with an Outcomes-driven Mixture of Experts for Patient Matching and Risk Estimation. ACM Transactions On Computing For Healthcare 2023, 4: 1-18. PMID: 37908872, PMCID: PMC10613929, DOI: 10.1145/3616021.Peer-Reviewed Original Research
2020
1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
SHARMA A, OFSTAD A, AHMAD T, ZINMAN B, ZWIENER I, FITCHETT D, WANNER C, GEORGE J, HANTEL S, DESAI N, MENTZ R. 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1144-p.Peer-Reviewed Original ResearchCV deathNovartis Pharmaceuticals CorporationPhenotype of patientsTreatment effectsEli LillyEMPA-REG OUTCOMERisk of outcomesType 2 diabetesAdvisory PanelBoehringer Ingelheim PharmaceuticalsBristol-Myers SquibbEMPA-REGMundipharma InternationalSanofi GenzymeCardiovascular deathCV diseaseT2D durationOlder patientsYounger patientsHeart failureAtherosclerotic diseaseSGLT2 inhibitionCox regressionDohme Corp.Patients